On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated ...

Amphastar Pharmaceuticals (AMPH) upgraded to Buy by Needham after FDA approval for generic iron sucrose injection, marking ...

According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to ...

The most common test used by sugar companies, such as American Crystal Sugar, is ICUMSA-420. Producers assign a color value ...

Viatris receives US FDA approval for generic iron sucrose injection to treat IDA in chronic kidney disease: Pittsburgh Tuesday, August 12, 2025, 18:00 Hrs [IST] Viatris Inc., a gl ...

Cognition Therapeutics shares rose 30% pre-market after the FDA confirmed its Phase 3 trial for Alzheimer's drug Zervimesine.

Viatris (VTRS) stock gains as the FDA OK its generic Iron Sucrose Injection targeting Venofer marketed by Daiichi Sankyo (DSKYF) (DSNKY) and Vifor. Read more here.

Amphastar Pharma’s iron sucrose injection receives US FDA approval to treat iron deficiency anaemia in patients with CKD: Rancho Cucamonga, California Tuesday, August 12, 2025, ...

Venofer was approved in the U.S. in 2000. It was developed by Vifor Pharma, which is now part of CSL Ltd. American Regent, a unit of Daiichi Sankyo, manufactures and sells it in the U.S. under a ...

Pharmaceuticals announced yesterday morning that the Food and Drug Administration approved the company’s abbreviated new drug ...

Iron sucrose injection is an iron replacement product indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease.

Investing.com -- Amphastar Pharmaceuticals (NASDAQ: AMPH) stock gained 4% after the company announced FDA approval for its generic version of iron sucrose injection, a treatment for iron deficiency ...